# US 2026/0224696 A1 · Modified carrier proteins for o-linked glycosylation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224696 A1
- Document ID: US20260224696A1
- Status: Published application
- Kind: A1
- Application number: 19/180,266
- Filed: 2025-04-16
- Published: 2026-08-06
- Earliest claimed: 2018-12-12
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals SA
- Inventors: Rainer FOLLADOR; Stefan Jochen KEMMLER; Michael Thomas KOWARIK; Gerald Johann POSCH
- Web page: https://patentgrep.com/patent/US20260224696A1

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- C07K 14/435: from animals; from humans
- A61K 39/0283: {Shigella}
- A61K 39/092: {Streptococcus}
- C07K 14/205: from Campylobacter (G)
- C07K 14/21: from Pseudomonadaceae (F)
- C07K 14/22: from Neisseriaceae (F)
- C07K 14/245: Escherichia (G)
- C07K 14/28: from Vibrionaceae (F)
- C07K 14/33: from Clostridium (G)
- C07K 14/34: from Corynebacterium (G)
- C12N 9/1048: {Glycosyltransferases (2.4)}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12P 21/005: {Glycopeptides, glycoproteins}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modified carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.

## Claims

### Claim 1

A modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof.

### Claim at position 2

2-18. (canceled)

### Claim 19 (depends on 1)

A method of making a conjugate, comprising contacting a PglL OTase and a PglL Glycan Substrate in the presence of a modified carrier protein, as in claim 1; thereby making the conjugate, then isolating the conjugate.

### Claim at position 4

20-24. (canceled)

### Claim 25

A method of O-glycosylation, wherein the method comprises:
(i) contacting a modified carrier protein comprising at least one GlycoTag, with a PglL homologue from N. gonorrhoeae or N. lactamica, wherein the at least one GlycoTag is a Neisseria meningitidis PglL GlycoTag (NmGlycoTag) consisting of a peptide sequence that is 12 to 29 amino acids long and wherein the peptide sequence comprises SEQ ID NO: 142; and
(ii) producing an O-glycosylated modified carrier protein.

### Claim 26 (depends on 25)

The method of claim 25 wherein producing comprises coupling, by the PglL homologue, a PglL Glycan Substrate to the modified carrier protein.

### Claim 27 (depends on 25)

The method of claim 25 further comprising isolating the O-glycosylated modified carrier protein from a bacterial host cell.

### Claim 28 (depends on 26)

The method of claim 26 wherein the reducing end of the PglL Glycan Substrate comprises a Glucose, Galactose, Galactofuranose, Rhamnose, GlcNAc, GalNAc, FucNAc, DATDH, GATDH, HexNAc, deoxy HexNAc, diNAcBac, or Pse.

### Claim 29 (depends on 28)

The method of claim 28 wherein the PglL Glycan Substrate is a glycan endogenous to a Neisseria, Shigella, Salmonella, Streptococcus, Escherichia, Pseudomonas, Yersinia, Campylobacter, or Heliobacter cell.

### Claim 30 (depends on 26)

The method of claim 26 wherein the PglL Glycan Substrate is endogenous to the host cell.

### Claim 31 (depends on 25)

The method of claim 25 further comprising isolating the O-glycosylated modified carrier protein from the periplasm of a cell.

### Claim 32 (depends on 25)

The method of claim 25 wherein the contacting occurs in the periplasm of a gram-negative bacterial cell.

### Claim 33 (depends on 25)

The method of claim 25 wherein the carrier protein is selected from the group consisting of cholera toxin b subunit (CTB), tetanus toxoid (TT), tetanus toxin C fragment (TTc), diphtheria toxoid (DT), CRM197, Pseudomonas aeruginosa exotoxin A (EPA), C. jejuni Acriflavine resistance protein A (CjAcrA), E. coli Acriflavine resistance protein A (EcAcrA), and Pseudomonas aeruginosa PcrV (PcrV).

### Claim 34 (depends on 25)

The method of claim 25, wherein the modified carrier protein is a Pseudomonas aeruginosa exotoxin A (EPA) carrier protein comprising at least one Neisseria meningitidis PglL GlycoTag (NmGlycoTag), wherein the at least one NmGlycoTag is located at, with respect to SEQ ID NO: 1, residue A14, D36, Q92, G123, E157, A177, Y208, N231, E252, R274, A301, Q307, A365, S408, T418, A464, A519, G525, A533, S585, K240, or A375, or combinations thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the at least one NmGlycoTag consists of a peptide sequence that is 12 to 19 amino acids long and comprises therein the sequence SEQ ID NO: 142.

### Claim 36 (depends on 25)

The method of claim 25, wherein the peptide sequence comprises SEQ ID NO: 141.

### Claim 37 (depends on 25)

The method of claim 25, wherein the peptide sequence comprises SEQ ID NO: 140.
